"The study enrolled 9 boys with confirmed Duchenne muscular dystrophy (DMD),ranging from 12 – 18 years of age. All were non-ambulant, meaning that the diseasehas reached the stage where patients are unable to walk more than a few metres."
I'm pretty keen to see more indepth analysis in January. I was wondering similar things re how the 2 trial groups may be different leading to the different results. People were not expecting the IIB to be as good as the IIA but the differences were so great that there needs to be greater explanation, imo.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)